TARO PHARMACEUTICAL INDS LTD's ticker is TARO and the CUSIP is M8737E108. A total of 126 filers reported holding TARO PHARMACEUTICAL INDS LTD in Q4 2017. The put-call ratio across all filers is 9.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,765,342 | -3.1% | 60,790 | 0.0% | 0.00% | – |
| Q3 2022 | $1,822,484 | -17.1% | 60,790 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $2,198,166 | -16.4% | 60,790 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $2,629,775 | -13.7% | 60,790 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $3,046,000 | -21.3% | 60,790 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,868,000 | -11.6% | 60,790 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,374,000 | -20.7% | 60,790 | -18.7% | 0.00% | 0.0% |
| Q1 2021 | $5,516,000 | -36.7% | 74,790 | -37.0% | 0.00% | -50.0% |
| Q4 2020 | $8,718,000 | +24.0% | 118,747 | -7.3% | 0.00% | 0.0% |
| Q3 2020 | $7,030,000 | -34.6% | 128,160 | -20.8% | 0.00% | -33.3% |
| Q2 2020 | $10,755,000 | -5.7% | 161,747 | -13.2% | 0.00% | -25.0% |
| Q1 2020 | $11,409,000 | -31.9% | 186,428 | -2.1% | 0.00% | -20.0% |
| Q4 2019 | $16,749,000 | +10.5% | 190,476 | -5.2% | 0.01% | 0.0% |
| Q3 2019 | $15,163,000 | -21.0% | 200,961 | -10.6% | 0.01% | -16.7% |
| Q2 2019 | $19,196,000 | -27.8% | 224,724 | -8.7% | 0.01% | -33.3% |
| Q1 2019 | $26,595,000 | +27.7% | 246,049 | 0.0% | 0.01% | +12.5% |
| Q4 2018 | $20,825,000 | -13.9% | 246,049 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $24,186,000 | -15.0% | 246,049 | 0.0% | 0.01% | -20.0% |
| Q2 2018 | $28,466,000 | +17.2% | 246,049 | 0.0% | 0.01% | +11.1% |
| Q1 2018 | $24,295,000 | -5.7% | 246,049 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $25,764,000 | +7.2% | 246,049 | +15.3% | 0.01% | 0.0% |
| Q3 2017 | $24,040,000 | +0.6% | 213,324 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $23,905,000 | -16.0% | 213,324 | -12.6% | 0.01% | -25.0% |
| Q1 2017 | $28,470,000 | +16.9% | 244,131 | +5.5% | 0.01% | +9.1% |
| Q4 2016 | $24,362,000 | +9.0% | 231,419 | +9.3% | 0.01% | 0.0% |
| Q3 2016 | $22,348,000 | -24.5% | 211,725 | +4.2% | 0.01% | -21.4% |
| Q2 2016 | $29,595,000 | +6.8% | 203,264 | +5.0% | 0.01% | 0.0% |
| Q1 2016 | $27,720,000 | -7.3% | 193,509 | 0.0% | 0.01% | -6.7% |
| Q4 2015 | $29,907,000 | +288.7% | 193,509 | +259.4% | 0.02% | +275.0% |
| Q3 2015 | $7,695,000 | – | 53,847 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 85,205 | $9,416,000 | 7.01% |
| FORT, L.P. | 149,014 | $16,468,000 | 5.67% |
| Strategic Global Advisors, LLC | 80,231 | $11,336,000 | 4.23% |
| MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC | 701,900 | $77,567,000 | 3.19% |
| Ativo Capital Management LLC | 78,727 | $8,700,000 | 2.01% |
| Analyst IMS Investment Management Services Ltd. | 31,438 | $3,474,000 | 1.47% |
| Parametrica Management Ltd | 4,327 | $478,000 | 1.32% |
| Freestone Capital Holdings, LLC | 89,005 | $9,836,000 | 0.90% |
| RPG Investment Advisory, LLC | 19,580 | $2,163,000 | 0.68% |
| MERITAGE PORTFOLIO MANAGEMENT | 38,465 | $4,251,000 | 0.47% |